Molecular structure of 4E1RCat, CAS Number: 328998-25-0
4E1RCat (CAS 328998-25-0)
Application:
4E1RCat is an inhibitor of protein translation
CAS Number:
328998-25-0
Purity:
≥95%
Molecular Weight:
478.45
Molecular Formula:
C28H18N2O6
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
4E1RCat is a chemical that functions as an inhibitor of the enzyme PARP-1. It acts by binding to the catalytic domain of PARP-1, preventing its activity and subsequent poly(ADP-ribosyl)ation of target proteins. This inhibition may disrupt the repair of single-strand DNA breaks and leads to the accumulation of DNA damage. As a result, 4E1RCat may have the functional role of inducing synthetic lethality in cancer cells with deficiencies in homologous recombination repair, such as those with BRCA mutations. By exploiting this mechanism of action, 4E1RCat may be used to selectively target cancer cells with specific DNA repair defects.
4E1RCat (CAS 328998-25-0) References
- Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F. | Cencic, R., et al. 2011. Proc Natl Acad Sci U S A. 108: 1046-51. PMID: 21191102
- Regulation of cardiac expression of the diabetic marker microRNA miR-29. | Arnold, N., et al. 2014. PLoS One. 9: e103284. PMID: 25062042
- CDK1 substitutes for mTOR kinase to activate mitotic cap-dependent protein translation. | Shuda, M., et al. 2015. Proc Natl Acad Sci U S A. 112: 5875-82. PMID: 25883264
- Crimean-Congo Hemorrhagic Fever Virus Nucleocapsid Protein Augments mRNA Translation. | Jeeva, S., et al. 2017. J Virol. 91: PMID: 28515298
- Salubrinal in Combination With 4E1RCat Synergistically Impairs Melanoma Development by Disrupting the Protein Synthetic Machinery. | Kardos, GR., et al. 2020. Front Oncol. 10: 834. PMID: 32637352
- Targeting SARS-CoV-2 nucleocapsid oligomerization: Insights from molecular docking and molecular dynamics simulations. | Ahamad, S., et al. 2022. J Biomol Struct Dyn. 40: 2430-2443. PMID: 33140703
- eIF4E-eIF4G complex inhibition synergistically enhances the effect of sorafenib in hepatocellular carcinoma. | Fang, C., et al. 2021. Anticancer Drugs. 32: 822-828. PMID: 33783376
- In Silico Drug Repurposing by Structural Alteration after Induced Fit: Discovery of a Candidate Agent for Recovery of Nucleotide Excision Repair in Xeroderma Pigmentosum Group D Mutant (R683W). | Takaoka, Y., et al. 2021. Biomedicines. 9: PMID: 33802476
- A noncanonical function of EIF4E limits ALDH1B1 activity and increases susceptibility to ferroptosis. | Chen, X., et al. 2022. Nat Commun. 13: 6318. PMID: 36274088
Inhibitor of:
(eukaryotic translation initiation factor) eIF, (eukaryotic translation initiation factor) eIF1, (eukaryotic translation initiation factor) eIF2, (eukaryotic translation initiation factor) eIF3, (eukaryotic translation initiation factor) eIF4, (eukaryotic translation initiation factor) eIF5, ABCE1, ARF7, DENR, E4F1, eIF1, eIF1AY, eIF2Bδ, eIF4B, eIF4E, eIF4G, eIF4H, eIF5A1, FTα, MUT, and neuroguidin.Activator of:
ATF-5, EG621697, and NPRL3.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
4E1RCat, 10 mg | sc-361085 | 10 mg | $193.00 | |||
4E1RCat, 50 mg | sc-361085A | 50 mg | $813.00 |